News Brazil Allows HempMeds to Import RSHO Cannabidiol for MS Treatment Brazil Allows HempMeds to Import RSHO Cannabidiol for MS Treatment by Patricia Silva, PhD | February 23, 2017 Share this article: Share article via email Copy article link The Brazilian government has authorizedĀ HempMeds Brasil, a unit of California-basedĀ Medical Marijuana, to import the parent company’sĀ hemp cannabidiol (CBD) oil flagship product ā known as Real Scientific Hemp Oil (RSHO) āĀ for the management of multiple sclerosis (MS) symptoms. This is the first time Brazil’s National Health Surveillance Agency (AgĆŖncia Nacional de VigilĆ¢ncia SanitĆ”ria, or ANVISA), has allowed RSHO prescriptions to be written specifically for MS patients. HempMeds Brasil became the first company in Brazil to offer legal medical cannabis products, in May 2015. The government now waives import taxes for RSHO, subsidizes its cost and covers the product under the countryās national health insurance program. Hemp belongs to the cannabis family,Ā but the CBD oil extracted from the plant has none of the psychoactive properties of other cannabis species, meaning patientsĀ receive the health benefits without getting high. In addition, hemp oil has high concentrations of CBD (which in itself contains healthy cannabinoids), terpenes and nutritious omega fatty acids and vitamins. “We commend the Brazilian government for recognizing nationwide health problems that exist, including multiple sclerosis and a multitude of other chronic medical conditions, and looking for solutions that can help alleviate those problems,” Stuart Titus, Medical Marijuanaās CEO, said in a press release.Ā “Brazil has embraced the therapeutic value of medical cannabinoids and is helping its people treat the symptoms of certain conditions with no known cure or limited treatment options.” More than 2.5 million people worldwide have been diagnosed with MS, according to the Multiple Sclerosis International Federation (MSIF). In Brazil, MS prevalenceĀ estimates vary widely, ranging between 1.36 and 27.2 per 100,000 people. CBD interacts with theĀ endocannabinoid systems (ECS) located in the brains and nervous systems of all mammals. Numerous studies have shown that such systemsĀ are directly involved in the processes that keep human bodiesĀ balanced on a daily basis ā helping people manage their appetite, mood, memory, tolerance for pain, immune functions and inflammations. The CBD inĀ hemp oil reacts directly with some of these receptors, stimulating ECS. In fact, many people may actually haveĀ an endocannabinoid deficiency, which could be sustained by the fact that no modern dietary variant contains cannabinoids. “Research findings suggest that cannabis could slow the neurodegenerative process of MS and help patients manage the symptoms associated with their disease,” Titus said.Ā “For instance, oneĀ studyĀ showed cannabinoids demonstrated neuroprotective effects during an animal model of MS, reducing the damage to myelin caused from inflammation, while in anotherĀ studyĀ MS patients saw significant improvements in muscle spasticity and reduced sleep disturbances after four weeks of cannabis treatments.ā Titus said HempMeds Brazil now markets a natural botanical CBD product, though the company’s pharmaceutical investment unit, AXIM Biotech,Ā is researching a novel chewing gum delivery method involving cannabinoids to specifically treat pain and muscular spasticity in European MS patients. Print This Page About the Author Patricia Silva, PhD PatrĆcia holds a PhD in medical microbiology and infectious diseases from the Leiden University Medical Center, Netherlands, and completed a postdoctoral research fellowship at the Instituto de Medicina Molecular, Lisbon, Portugal. Her work in academia was mainly focused on molecular biology and the genetic traits of infectious agents such as viruses and parasites. PatrĆcia earned several travel awards to present her work at international scientific meetings. She is a published author of several peer-reviewed science articles. Tags cannabinoids, inflammation, medical marijuana, spasticity
April 26, 2024 News by Marisa Wexler, MS Machine learning model predicts CIS to MS conversion risk: Study
April 25, 2024 Columns by Benjamin Hofmeister Finding safety while living with the constant threat of MS progression
April 25, 2024 News by Margarida Maia, PhD Having MS may marginally increase likelihood of cervical cancer: Study